Mammary Cell News 8.32 August 18, 2016 | |
| |
TOP STORYTumor Hypoxia Causes DNA Hypermethylation by Reducing TET Activity Scientists showed increased hypoxia in mouse breast tumors increases hypermethylation, while restoration of tumor oxygenation abrogates this effect. Tumor hypoxia therefore acts as a novel regulator of DNA methylation. [Nature] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)LABORATORY RESEARCHPunctuated Copy Number Evolution and Clonal Stasis in Triple-Negative Breast Cancer Researchers developed a highly multiplexed single-nucleus sequencing method to investigate copy number evolution in patients with triple-negative breast cancer. [Nat Genet] Abstract | Press Release Twist1 Promotes Breast Cancer Invasion and Metastasis by Silencing Foxa1 Expression Researchers demonstrated that in the estrogen receptor-positive luminal breast cancer cells Twist1 silences Foxa1 expression, which has an essential role in relieving Foxa1-arrested migration, invasion and metastasis of breast cancer cells. [Oncogene] Abstract Interactions between the various cell types that constitute a solid tumor are essential to the biology of the tumor. Investigators evaluated the effect of morphine on the proangiogenic interaction taking place between macrophages and breast cancer cells in vitro. [Sci Rep] Full Article Tyrosine kinase activity of the asymmetric epidermal growth factor receptor (EGFR) homodimer is negatively regulated via ERK-mediated phosphorylation of Thr-669 in the juxtamembrane domain. Scientists investigated in human breast cancer cells whether a similar mechanism plays a role in the feedback regulation of the ErbB2/ErbB3 heterodimer, the most potent ErbB receptor dimer. [Sci Rep] Full Article Scientists have discovered that the metastasis-promoting phosphatase, PRL-3, is transcriptionally regulated by the NF-ĸB pathway in triple-negative breast cancer cells (TNBC), and that PRL-3 knockdown elicits an autocrine tumor necrosis factor receptor 1 (TNF-R1) feedback loop that results in TNBC cell senescence followed by apoptosis. [Oncogenesis] Full Article Investigators found that RNF168 cooperates with RNF8 to mediate the ubiquitination and degradation of SUMOylated forkhead box M1 (FOXM1) in breast cancer genotoxic response. [Oncogenesis] Full Article Researchers performed a systematic phenotypic screen and characterized the adhesion properties of a panel of human HER2 amplified breast cancer cell lines across six extracellular matrix proteins commonly deregulated in breast cancer. [Oncotarget] Full Article | Press Release Investigators identified prognostic biomarkers for tamoxifen resistance and to reveal the underlying mechanism. [Oncotarget] Full Article Researchers investigated cellular responses to alcohol in two triple-negative breast cancer cell lines. The results showed that alcohol at low concentrations induced cell proliferation, migration, and invasion in 1% FBS-containing medium. [Mol Carcinog] Abstract CLINICAL RESEARCHInvestigators determined the prevalence of estrogen receptor α (ESR1) mutations in estrogen receptor-positive metastatic breast cancer and determined whether mutation is associated with inferior outcomes. [JAMA Oncol] Abstract | |
| |
REVIEWSBreast Cancer Stem Cell: The Roles and Therapeutic Implications The authors summarize current literature about the diversity of breast cancer stem cell (BCSC) markers, the roles of BCSCs in tumor development, and the regulatory mechanisms of BCSCs. They also highlight the most recent advances in BCSC targeting therapies and the challenges in translating the knowledge into clinical practice. [Cell Mol Life Sci] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSThousands of NHS Patients Missing Out on Cancer Treatments Available in Other Countries New international report finds access to breast cancer drugs across the UK is falling behind other countries – including Germany, France and Canada – with thousands missing out on life-extending treatments. [Breast Cancer Now] Press Release Evgen Pharma Plc. Clinical Trial Approval for Phase II Study in Breast Cancer Evgen Pharma plc. announced that it has received a clinical trial approval from the UK’s regulatory agency for the commencement of its Phase II clinical trial of SFX‐01 in breast cancer. [Evgen Pharma plc. (DirectorsTalk Interviews)] Press Release Two New Drugs Show Promise for Patients with Aggressive Breast Cancer Results from I-SPY 2 study may lead to smaller, faster and more focused Phase III trials of new therapies for patients with triple-negative and HER2-positive breast cancer [University of Pennsylvania] Press Release | |
| |
POLICY NEWSA new measurement standard developed by the National Institute of Standards of Technology has been used successfully by the Frederick National Laboratory for Cancer Research to check the performance of next-generation DNA-sequencing technologies for evaluating gene variations associated with an increased risk of breast cancer. [National Institute of Standards of Technology] Editorial US Personalized-Medicine Industry Takes Hit from Supreme Court Rejections for US patents related to personalized medicine have spiked after recent Supreme Court decisions tightened the rules for such claims, an analysis of more than 39,000 patent applications reveals. [Nature News] Editorial Candidate Cancer Drug Suspected after Death of Three Patients at an Alternative Medicine Clinic A new type of cancer drug developed at Johns Hopkins University in Baltimore, Maryland, but not yet tested in clinical trials may have triggered the deaths of three patients who were undergoing an alternative cancer treatment by a nonmedical practitioner in Germany. [ScienceInsider] Editorial
| |
EVENTSNEW 2016 National Cancer Research Institute Cancer Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral and PhD Positions – Personalized Medicine for Breast Cancer (University of Basel) Product Specialist – Oncology (Celgene Corporation) Robert Stowell Chair – Experimental Pathology (University of California, Davis) Lead Bioinformatitian – Cancer-Related Genes and Targeted Drugs (Institute of Cancer Research) Postdoctoral Position – Metastatic Reactivaction of Cancer (MD Anderson Cancer Center) Scientific Director – Oncology (Merck) Postdoctoral Fellow – Various Projects (National University of Singapore) Postdoctoral Fellow – Breast Cancer Monitoring through Digital Imaging (University Rovira i Virgili) Postdoctoral Researcher – Basic & Translational Breast Cancer Research (Northwestern University) Postdoctoral Associate – Premalignant Progression to Invasive Breast Cancer (Tulane Medical School) Postdoctoral Fellowship – Cancer Research (German Cancer Research Center) Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center) Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Mammary Cell News Volume 8.32 | Aug 18 2016